Acquisition of Zavante (Details) - Zavante Therapeutics $ in Millions	Jul. 24, 2018 USD ($) shares
Acquisition of Zavante
Percentage of entity shares held by subsidiary	19.90%
In-process research and development expense	$ 32.0
Fair value of upfront shares issued	26.9
Research and development expense, dealing costs	4.9
Net liabilities assumed	0.2
Maximum
Acquisition of Zavante
Contingent consideration payment	97.5
Approval Milestone Payment
Acquisition of Zavante
Contingent consideration payment	25.0
Net Sales Milestone Payments
Acquisition of Zavante
Contingent consideration payment	$ 72.5
Upfront Shares
Acquisition of Zavante
Business acquisition, ordinary shares issued or issuable \| shares	7,336,906
Holdback Shares, as a percentage of Upfront Shares	10.00%
Holdback Shares
Acquisition of Zavante
Business acquisition, ordinary shares issued or issuable \| shares	815,186

Represents the amount of business combination, In-research and development expense.

No definition available.

Name:	nbrv_BusinessCombinationInProcessResearchAndDevelopmentExpense
Namespace Prefix:	nbrv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage of shares issued in business combination which will serve as a source for the satisfaction of indemnification and other obligations of the former Zavante stockholders and, subject to reduction in respect of these obligations, will be issued to the former Zavante stockholders following the first anniversary of the Closing.

+ References

No definition available.

+ Details

Name:	nbrv_BusinessCombinationPercentageOfSharesIssuedIndemnificationOfFormerStockholders
Namespace Prefix:	nbrv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the amount of business combination, research and development expense dealing costs.

+ References

No definition available.

+ Details

Name:	nbrv_BusinessCombinationResearchAndDevelopmentExpenseDealingCosts
Namespace Prefix:	nbrv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of business combination, fair value of upfront shares included in research and development expense.

+ References

No definition available.

+ Details

Name:	nbrv_BusinessCombinationResearchAndDevelopmentExpenseFairValueOfUpfrontShares
Namespace Prefix:	nbrv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Percentage of entity shares held by subsidiary.

+ References

No definition available.

+ Details

Name:	nbrv_CommonStockOutstandingHeldBySubsidiaryPercentage
Namespace Prefix:	nbrv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of shares of equity interests issued or issuable to acquire entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of liabilities assumed at the acquisition date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472

+ Details

Name:	us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_BusinessAcquisitionAxis=nbrv_ZavanteTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nbrv_ApprovalMilestonePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nbrv_NetSalesMilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nbrv_UpfrontSharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nbrv_HoldbackSharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: